Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Genentech disappointed with FDA ODAC's recommendation against Avastin

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one that use of Avastin® (bevacizumab) in combination with paclitaxel for previously untreated (first-line) advanced HER2-negative breast cancer be removed from Avastin's U.S. label.

21 Jul 2010

Hybrid Linac-MR imaging system tracks cancer tumors in real time

Today, at the 52nd Annual Meeting of the American Association of Physicists in Medicine (AAPM) in Philadelphia, a group of researchers from Stanford University will describe the latest developments toward their goal of integrating two existing medical devices -- medical linear accelerators, or "linacs," which produce powerful X-rays for treating cancer, and magnetic resonance imagers (MRIs), which are widely used to image tumors in the human body.

21 Jul 2010

JHM, All Children's Hospital sign letter of intent to integrate

Johns Hopkins Medicine and All Children's Hospital & Health System of St. Petersburg, Fla., have signed a letter of intent to integrate. After appropriate due diligence is completed sometime later this year, ACH will join the Johns Hopkins Health System (JHHS) as a fully integrated member of JHM.

21 Jul 2010

GCSF administration can reduce side effects of cancer neurobastoma in children

Children given a hormone growth factor alongside chemotherapy for the aggressive cancer neuroblastoma are less likely to suffer a potentially deadly side-effect, according to a major international study published today (Tuesday) in the Journal of Clinical Oncology.

21 Jul 2010

Prostate cancer: To screen or not to screen

Men with a family history of prostate cancer who are confused about whether to undergo controversial screening could soon have access to an online resource to have their questions answered.

20 Jul 2010

Access selects BioScrip as exclusive distribution and service partner for MuGard

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has signed an exclusive specialty distribution agreement with BioScrip for its lead product, MuGard -- an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy.

20 Jul 2010

Archer Biosciences initiates third drug-escalation cohort in TPI-287 trial for metastatic melanoma

Archer Biosciences, Inc. announced that the trial of its novel, proprietary drug TPI-287 (an abeotaxane) for the treatment of metastatic melanoma has initiated a third drug-escalation cohort. The primary objective of this study is to determine the safety, tolerability and maximum tolerated dose (MTD) of TPI-287 in combination with temozolomide (TMZ) in adult patients with metastatic melanoma.

20 Jul 2010

Inergetics receives CPR to market Resurgex Select product as nutritional supplement

Inergetics, Inc., a leader in targeted product development for the Clinical Nutrition and Sports Supplement Markets, today announced that the Company has received a Certificate of Product Registration from the FDA Philippines, certifying that its Resurgex Select product can now be marketed as a nutritional supplement for cancer patients and other immune-compromised individuals throughout the country.

20 Jul 2010

Seattle Genetics, Agensys commence ASG-5ME ADC phase I clinical trial for metastatic pancreatic cancer

Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors.

20 Jul 2010

Frameless radiosurgery can treat most sensitive regions of brain: Study

While four in 10 clinicians use frameless radiosurgery exclusively to treat cranial indications, user data collected at the 5th International Conference of the Novalis Circle, held last month in Munich, Germany, shows that there are still significant opportunities to increase utilization of the effective treatment approach.

20 Jul 2010

Meridian Bioscience completes acquisition of Bioline group of companies

Meridian Bioscience, Inc., Cincinnati, Ohio announces that effective today it will have completed the purchase of all the outstanding capital stock of the Bioline group of companies consisting of Bioline Ltd (UK), Bioline GmbH (Germany), Bioline (Aust) Pty Ltd (Australia), Bioline Reagents Ltd, and Bioline USA, Inc for $23.3 million in cash on hand.

20 Jul 2010

SHFL to upgrade to latest version of NetSol's LeaseSoft asset management solution

NetSol Technologies, Inc., a U.S. corporation providing global business services and enterprise application solutions to private and public sector organizations worldwide, today announced that the Company has signed a LeaseSoft license upgrade agreement with Singers Healthcare Finance Limited, one of the UK's leading providers of leasing solutions to the healthcare industry.

20 Jul 2010

ASTRO accepts 4 abstracts on Stereotactic Body Radiation Therapy for NSCLC

The American Society for Radiation Oncology (ASTRO) has accepted four abstracts from users of Elekta Stereotactic Body Radiation Therapy (SBRT) technology on the use of SBRT to treat non-small cell lung cancer (NSCLC). The clinicians will present their findings during presentations at ASTRO's 52nd Annual Meeting (October 31 - November 4) at the San Diego Convention Center.

From Elekta 20 Jul 2010

Aegera reports data from Phase 1 portion of combination AEG35156 Phase 1-2 study for primary liver cancer

Aegera Therapeutics Inc. released today encouraging survival data from the Phase 1 portion of its Phase 1-2 Study of the novel targeted therapeutic, AEG35156, given in combination with sorafenib in patients with advanced hepatocellular carcinoma (primary liver cancer).

20 Jul 2010

New approach to understand different cancer subtypes

An international team led by St. Jude Children's Research Hospital scientists finds unique combinations of cells and mutations lie at the heart of cancer subgroup revealed for the first time in a pediatric brain tumor

20 Jul 2010

Rottapharm Madaus, Selvita sign drug discovery services contract

Rottapharm Madaus and Selvita announced today signature of a services contract for delivery of drug discovery services. The aim of this project is to deliver to Rottapharm Madaus a set of designed and synthesized compounds, including their optimized synthesis route, which will have a therapeutic potential in an indicated area.

20 Jul 2010

Case Western Reserve awarded $0.5M for study of breast cancer in older women

Cynthia Owusu, MD, associate professor at Case Western Reserve University and geriatric-oncologist at University Hospitals Case Medical Center, the School's primary affiliate, has received nearly $500,000 from Susan G. Komen For the Cure to fund a novel three-year study aimed at improving outcomes for older women with newly-diagnosed breast cancer.

20 Jul 2010

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

A Phase 3 open-label study, recently published online by Pain Practice, has compared tapentadol extended release tablets, an investigational pain medication, to an existing prescription pain medication, oxycodone controlled release tablets.

20 Jul 2010

CytRx updates on progress in clinical development of bafetinib in three oncology indications

CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.

20 Jul 2010

ZIOPHARM Oncology commences palifosfamide Phase III clinical trial for metastatic soft tissue sarcoma

ZIOPHARM Oncology, Inc. today announced the initiation of the pivotal Phase III clinical trial for palifosfamide in patients with front-line metastatic soft tissue sarcoma. The study, called PICASSO 3, is an international, randomized, double-blinded, placebo-controlled trial designed to enroll approximately 424 patients with metastatic soft tissue sarcoma who have never been treated with chemotherapy for metastatic disease.

20 Jul 2010

Oncology News and Research

Further Reading

Genentech disappointed with FDA ODAC's recommendation against Avastin

Hybrid Linac-MR imaging system tracks cancer tumors in real time

JHM, All Children's Hospital sign letter of intent to integrate

GCSF administration can reduce side effects of cancer neurobastoma in children

Prostate cancer: To screen or not to screen

Access selects BioScrip as exclusive distribution and service partner for MuGard

Archer Biosciences initiates third drug-escalation cohort in TPI-287 trial for metastatic melanoma

Inergetics receives CPR to market Resurgex Select product as nutritional supplement

Seattle Genetics, Agensys commence ASG-5ME ADC phase I clinical trial for metastatic pancreatic cancer

Frameless radiosurgery can treat most sensitive regions of brain: Study

Meridian Bioscience completes acquisition of Bioline group of companies

SHFL to upgrade to latest version of NetSol's LeaseSoft asset management solution

ASTRO accepts 4 abstracts on Stereotactic Body Radiation Therapy for NSCLC

Aegera reports data from Phase 1 portion of combination AEG35156 Phase 1-2 study for primary liver cancer

New approach to understand different cancer subtypes

Rottapharm Madaus, Selvita sign drug discovery services contract

Case Western Reserve awarded $0.5M for study of breast cancer in older women

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

CytRx updates on progress in clinical development of bafetinib in three oncology indications

ZIOPHARM Oncology commences palifosfamide Phase III clinical trial for metastatic soft tissue sarcoma

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News